Yun H, et al. Do Patients with Moderate or High Disease Activity Escalate RA Therapy According to Treat-to-Target Principles? Results from the ACR’s RISE Registry. ACR 2018, abstract 2856.
Besparing door inzet biosimilars loopt op tot bijna 800 miljoen per jaar
mei 2024